Literature DB >> 1690681

Hyperamylasemia associated with progression of a serous surface papillary carcinoma.

T O'Riordan1, E Gaffney, V Tormey, P Daly.   

Abstract

A 60-year-old white woman had a bilateral salpingo-oophorectomy, hysterectomy, and omentectomy for serous surface papillary carcinoma. Combination chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide was given for 1 year, but was followed by relapse 4 months after completion. This relapse was associated with hyperamylasemia ranging from 2400 IU/liter in the early phase of relapse to 5800 IU/liter in the preterminal phase. While hyperamylasemia has been previously described in serous ovarian cystadenocarcinoma, to our knowledge this is the first report in a patient with serous surface papillary carcinoma. This marker may help in distinguishing the latter from malignant mesothelioma of the peritoneum since this is often an extremely difficult differential diagnosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1690681     DOI: 10.1016/0090-8258(90)90158-h

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  Hyperamylasaemia: not the usual suspects.

Authors:  Rajeev Srivastava; Callum Fraser; Douglas Gentleman; Lynne A Jamieson; Michael J Murphy
Journal:  BMJ       Date:  2005-10-15

2.  A multidisciplinary approach to an unusual cause of hyperamylasaemia.

Authors:  James John Logie; Mary Cox; Joanne Sharkey; Alistair Williams
Journal:  BMJ Case Rep       Date:  2015-07-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.